NZ624714A - Methods for treating gout in patient subpopulations - Google Patents

Methods for treating gout in patient subpopulations

Info

Publication number
NZ624714A
NZ624714A NZ624714A NZ62471411A NZ624714A NZ 624714 A NZ624714 A NZ 624714A NZ 624714 A NZ624714 A NZ 624714A NZ 62471411 A NZ62471411 A NZ 62471411A NZ 624714 A NZ624714 A NZ 624714A
Authority
NZ
New Zealand
Prior art keywords
methods
medicament
treating gout
renal function
patient subpopulations
Prior art date
Application number
NZ624714A
Other languages
English (en)
Inventor
Brian K Roberts
Gopal Chandra Saha
Brian Edward Lavan
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of NZ624714A publication Critical patent/NZ624714A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ624714A 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations NZ624714A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (1)

Publication Number Publication Date
NZ624714A true NZ624714A (en) 2016-01-29

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ624714A NZ624714A (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Country Status (14)

Country Link
EP (1) EP2775835A4 (enrdf_load_stackoverflow)
JP (1) JP6047172B2 (enrdf_load_stackoverflow)
KR (1) KR101848122B1 (enrdf_load_stackoverflow)
CN (1) CN104066323A (enrdf_load_stackoverflow)
AU (1) AU2011380509B2 (enrdf_load_stackoverflow)
BR (1) BR112014010693A2 (enrdf_load_stackoverflow)
CA (1) CA2859689C (enrdf_load_stackoverflow)
CL (1) CL2014001156A1 (enrdf_load_stackoverflow)
IL (1) IL232385A (enrdf_load_stackoverflow)
MX (1) MX354846B (enrdf_load_stackoverflow)
NZ (1) NZ624714A (enrdf_load_stackoverflow)
SG (1) SG11201402027PA (enrdf_load_stackoverflow)
WO (1) WO2013066352A1 (enrdf_load_stackoverflow)
ZA (1) ZA201403574B (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
CN105851522A (zh) * 2014-07-25 2016-08-17 许伟琦 一种防止尿路结石的饲料
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CN102643241B (zh) * 2007-11-27 2015-01-21 亚德生化公司 化合物和组合物以及使用方法

Also Published As

Publication number Publication date
CL2014001156A1 (es) 2015-01-16
KR20140123927A (ko) 2014-10-23
KR101848122B1 (ko) 2018-04-11
IL232385A0 (en) 2014-06-30
MX2014005399A (es) 2015-04-08
CA2859689A1 (en) 2013-05-10
WO2013066352A1 (en) 2013-05-10
EP2775835A4 (en) 2015-07-29
JP2014532759A (ja) 2014-12-08
MX354846B (es) 2018-03-22
BR112014010693A2 (pt) 2020-11-10
SG11201402027PA (en) 2014-09-26
EP2775835A1 (en) 2014-09-17
CN104066323A (zh) 2014-09-24
CA2859689C (en) 2018-05-22
JP6047172B2 (ja) 2016-12-21
AU2011380509B2 (en) 2016-05-19
ZA201403574B (en) 2015-11-25
AU2011380509A1 (en) 2014-05-29
IL232385A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
MY199017A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
WO2012081898A3 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
MX2014001946A (es) Inhibidores del canal de potasio medularmente externo renal.
AU2012214029A8 (en) Rorgammat inhibitors
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
IN2014MN02089A (enrdf_load_stackoverflow)
UA115320C2 (uk) Інгібітори кінази
NZ601167A (en) Treatment of cardiac conditions
MX2015013944A (es) Inhibidor de quinasa.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
EA201390335A1 (ru) Введение лоркасерина индивидуумам с почечной недостаточностью
WO2015095097A3 (en) Inhibitors of the renal outer medullary potassium channel
MY167216A (en) Kinase inhibitors
EP3065734A4 (en) Ferric citrate for reducing cardiac failure in chronic kidney disease patients
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
NZ624714A (en) Methods for treating gout in patient subpopulations
JP2014532758A5 (enrdf_load_stackoverflow)
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
MX2013014398A (es) Derivados de sulfonamida heterociclicos.
EA201190256A1 (ru) Способ снижения уровня убиквитинилированных белков
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 NOV 2018 BY AJ PARK

Effective date: 20160726

ASS Change of ownership

Owner name: CYMABAY THERAPEUTICS, INC., US

Effective date: 20170309

Owner name: DIATEX, INC., NZ

Effective date: 20170309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2019 BY CPA GLOBAL

Effective date: 20180920

LAPS Patent lapsed